Table 1.
Baseline characteristics of the 106 subjects who were included in this analysis
| Daily dose by study Group Variable | Testosterone 5 g
|
Testosterone 10 g
|
P valuea | ||||
|---|---|---|---|---|---|---|---|
| GH 0 (n = 19) Group A | GH 3 μg (n = 17) Group B | GH 5 μg (n = 20) Group C | GH 0 (n = 19) Group D | GH 3 μg (n = 15) Group E | GH 5 μg (n = 16) Group F | ||
| Age (yr) | 72.7 ± 5.1 | 71.4 ± 4.1 | 70.0 ± 4.1 | 69.9 ± 4.5 | 69.2 ± 2.5 | 70.8 ± 3.8 | 0.24b |
| Ethnicity/race | |||||||
| Caucasian | 14 (74%) | 17 (100%) | 18 (90%) | 14 (74%) | 13 (87%) | 16 (100%) | 0.27 |
| Minority | 5 (26%) | 0 (0%) | 2 (10%) | 5 (26%) | 2 (13%) | 0 (0%) | |
| Hormones | |||||||
| Total testosterone (ng/dl) | 385 ± 107 | 383 ± 101 | 373 ± 89 | 355 ± 97 | 372 ± 85 | 302 ± 90 | 0.13 |
| IGF-I (ng/ml) | 101 ± 23 | 108 ± 25 | 115 ± 31 | 108 ± 29 | 130 ± 31 | 112 ± 32 | 0.10b |
| Body composition | |||||||
| Weight (kg) | 79.1 ± 10.4 | 81.6 ± 12.9 | 85.7 ± 11.2 | 85.1 ± 13.9 | 85.4 ± 14.5 | 83.2 ± 11.6 | 0.54 |
| BMI (kg/m2) | 26.8 ± 3.5 | 26.1 ± 3.0 | 28.2 ± 3.2 | 28.4 ± 3.8 | 27.2 ± 3.4 | 27.3 ± 3.3 | 0.33 |
| Total LBM (kg) | 55.6 ± 5.0 | 58.7 ± 8.2 | 59.2 ± 8.1 | 58.9 ± 6.2 | 58.0 ± 6.9 | 58.3 ± 4.9 | 0.60 |
| Appendicular LBM (kg) | 24.2 ± 2.4 | 25.7 ± 3.7 | 26.0 ± 3.7 | 25.7 ± 2.8 | 25.3 ± 3.4 | 25.6 ± 2.4 | 0.56 |
| Muscle performance | |||||||
| VO2 peak (ml/kg · min) | 23.9 ± 6.2 | 26.4 ± 4.0 | 24.1 ± 3.5 | 24.3 ± 6.9 | 23.9 ± 3.9 | 25.3 ± 4.2 | 0.72 |
| P3NP (ng/ml) | 4.7 ± 1.2 | 4.4 ± 1.0 | 4.5 ± 0.9 | 4.7 ± 1.1 | 4.2 ± 1.0 | 4.4 ± 1.0 | 0.76 |
Data are mean ± sd. VO2, O2 consumption.
a
ANOVA for continuous variables and χ2 test for discrete variables (e.g. ethnicity) was used.
b
From Kruskal-Wallis test.